Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 31, 2013 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium

CARMIEL, Israel, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical data on taliglucerase alfa will be presented at the 9th...
December 10, 2012 02:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102

CARMIEL, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company's phase I/II...
December 06, 2012 07:44 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)

CARMIEL, Israel, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has entered into a Clinical Development Agreement with Pfizer Inc....
December 05, 2012 02:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York City

CARMIEL, Israel, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that Yossi Maimon, the Company's Vice President and Chief Financial Officer,...
November 08, 2012 09:29 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the 2012 Jefferies Global Healthcare Conference in London

CARMIEL, Israel, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today announced that Yossi Maimon, the Company's Vice President and Chief Financial Officer,...
November 01, 2012 10:33 ET | Source: Protalix BioTherapeutics, Inc.

European Commission Issues Decision on Taliglucerase Alfa Marketing Authorization Application

NEW YORK and CARMIEL, Israel, Nov. 1, 2012 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX) today announced that the European Commission (EC) has...
September 27, 2012 06:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Receives Marketing Authorization for Elelyso(TM) for the Treatment of Gaucher Disease From the Israeli Ministry of Health

CARMIEL, Israel, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that is has received marketing authorization from the Israeli Ministry of...
September 12, 2012 02:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the UBS Global Life Sciences Conference

CARMIEL, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer,...
August 13, 2012 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102, a Modified Enzyme Replacement Therapy

CARMIEL, Israel, Aug. 13, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has received clearance of its Investigational New Drug (IND)...
August 09, 2012 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the Canaccord Genuity 32nd Annual Growth Conference

CARMIEL, Israel, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX) announced today that Yossi Maimon, the Company's Chief Financial Officer, will present at the...